Related Experiment Video
Updated: Feb 8, 2026

Pan-lyssavirus Real Time RT-PCR for Rabies Diagnosis
Published on: July 10, 2019
A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection
Yan Wang1, Jeffrey S Glenn2, Mark A Winters2
1State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Clinical Center for HIV/AIDS, Capital Medical University, Beijing, P.R. China.
Abstract:
In this study, a real-time reverse transcription-polymerase chain reaction (real time RT-PCR) assay targeting 2 genetic segments was established to detect HDV RNA. Utilizing the World Health Organization International Standard for Hepatitis D Virus RNA, the lower limit of detection was 575 IU/mL, and the linearity of quantification ranged from 575,000 IU/mL to 575 IU/mL. 384 HBsAg-positive samples collected from China were tested by this method and HDV antibody detection. Eleven samples were positive for anti-HDV IgG which may persist after HDV resolution, 6 samples were HDV RNA positive, and 5 samples were positive for anti-HDV IgM. This assay showed more sensitivity than the detection of anti-HDV IgM. These data demonstrate that the real-time RT-PCR assay for HDV RNA could be implemented in the clinical detection of HDV infection in chronic HBV-infected patients in China.
Related Concept Videos
Real Time RT-PCR
The real-time quantification of the number of amplified products is...
Viruses with RNA Genomes
What are Viruses?
PCR
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

